Transcription and Translation Inhibitors in Cancer Treatment

@article{1672938,
   author = {LahamandKaram, Nihay and Rangel Pamplona Pizarro Pinto, José Gaspar and Poso, Antti and Kokkonen, Piia Pauliina},
   article_location = {Lausanne},
   article_number = {April 2020},
   doi = {http://dx.doi.org/10.3389/fchem.2020.00276},
   keywords = {cancer; drug; inhibitor; translation; transcription},
   language = {eng},
   issn = {2296-2646},
   journal = {Frontiers in Chemistry},
   title = {Transcription and Translation Inhibitors in Cancer Treatment},
   url = {https://www.frontiersin.org/articles/10.3389/fchem.2020.00276/full},
   volume = {8},
   year = {2020}
}

TY  - JOUR
ID  - 1672938
AU  - Laham-Karam, Nihay - Rangel Pamplona Pizarro Pinto, José Gaspar - Poso, Antti - Kokkonen, Piia Pauliina
PY  - 2020
TI  - Transcription and Translation Inhibitors in Cancer Treatment
JF  - Frontiers in Chemistry
VL  - 8
IS  - April 2020
SP  - 1-24
EP  - 1-24
PB  - Frontiers Media SA
SN  - 22962646
KW  - cancer
KW  - drug
KW  - inhibitor
KW  - translation
KW  - transcription
UR  - https://www.frontiersin.org/articles/10.3389/fchem.2020.00276/full
L2  - https://www.frontiersin.org/articles/10.3389/fchem.2020.00276/full
N2  - Transcription and translation are fundamental cellular processes that govern the protein production of cells. These processes are generally up regulated in cancer cells, to maintain the enhanced metabolism and proliferative state of these cells. As such cancerous cells can be susceptible to transcription and translation inhibitors. There are numerous druggable proteins involved in transcription and translation which make lucrative targets for cancer drug development. In addition to proteins, recent years have shown that the "undruggable" transcription factors and RNA molecules can also be targeted to hamper the transcription or translation in cancer. In this review, we summarize the properties and function of the transcription and translation inhibitors that have been tested and developed, focusing on the advances of the last 5 years. To complement this, we also discuss some of the recent advances in targeting oncogenes tightly controlling transcription including transcription factors and KRAS. In addition to natural and synthetic compounds, we review DNA and RNA based approaches to develop cancer drugs. Finally, we conclude with the outlook to the future of the development of transcription and translation inhibitors.
ER  - 

LAHAM-KARAM, Nihay, José Gaspar RANGEL PAMPLONA PIZARRO PINTO, Antti POSO a Piia Pauliina KOKKONEN. Transcription and Translation Inhibitors in Cancer Treatment. \textit{Frontiers in Chemistry}. Lausanne: Frontiers Media SA, 2020, roč.~8, April 2020, s.~1-24. ISSN~2296-2646. Dostupné z: https://dx.doi.org/10.3389/fchem.2020.00276.